

News and Deals

1. Dash Bio: \$30M Series A to accelerate automated bioanalysis for drug development | Aug. 3, 2026

Waltham-based Dash Bio raised a Series A led by Oak HC/FT, with Freestyle Capital and Swift Ventures participating. The company is scaling a GLP-compliant, automation-first bioanalysis platform designed to shorten preclinical and clinical sample-testing timelines.

HDIG take: Life-science infrastructure: targets a persistent CRO bottleneck with robotics, software and AI-enabled lab operations. [LINK](#)

2. Claris Biotherapeutics: \$118M Series B to fund pivotal work in limbal stem cell deficiency | Jul. 28, 2026

Claris announced a \$118M Series B co-led by Samsara BioCapital and Catalio Capital Management, alongside leadership appointments. Proceeds are expected to support ongoing studies and a planned 1H 2027 pivotal program for CSB-001 in LSCD.

HDIG take: Late-stage ophthalmology platform with strong specialty-pharma relevance and clear clinical-development use of proceeds. [LINK](#)

3. CORE Biomedicine: \$21M Series A plus AMED grant to advance lineage-based oncology therapeutics

| Jul. 28, 2026

CORE Biomedicine completed a Series A co-led by UTokyo Innovation Platform and Elikon Venture, with participation from investors across the U.S., Japan and China. The financing and AMED grant support discovery and early clinical development.

HDIG take: Precision oncology: a genomics-adjacent therapeutic strategy aimed at broader tumor-lineage biology. [LINK](#)

4. Epitel: \$26M Series B to expand remote wireless EEG monitoring | Jul. 28, 2026

Epitel closed a Series B co-led by Catalyst Health Ventures and Genoa Ventures to expand commercialization of its REMI remote EEG monitoring system and REMI Vigilenz AI event-detection software.

HDIG take: Digital neurology: extends EEG access outside traditional hospital-based monitoring capacity. [LINK](#)

5. Procode: \$10M Series A for AI-powered surgical medical billing | Jul. 28, 2026

Procode raised a Series A led by Health Velocity Capital to expand its AI-enabled RCM platform and pursue additional specialty billing acquisitions after buying The Auctus Group.

HDIG take: Provider operations: applies purpose-built AI to a high-friction revenue-cycle workflow for private-practice surgeons and ASCs. [LINK](#)

6. Aurenar: \$5.7M Seed for non-invasive ICU neuromodulation platform | Jul. 28, 2026

Aurenar closed an oversubscribed seed round co-led by the Go Red for Women Venture Fund and Solas BioVentures, with BJC Health and Kaleida Capital participating. Proceeds will support device development, V&V testing and regulatory submissions.

HDIG take: Medtech seed-stage signal: targets life-threatening stroke complications in the ICU with a single-use platform. [LINK](#)

7. Adjuvia Therapeutics: \$8M Series Seed to advance mitochondrial disease therapy ATI-105 | Jul. 29, 2026

Adjuvia raised \$8M led by JLO Ventures, with Portfolia Ventures and biopharma executives participating. The company plans to support an IND submission and start Phase 1 clinical testing in fall 2026.

HDIG take: Early biotech: financing moves a mitochondrial dysfunction program toward first-in-human development. [LINK](#)

8. Qureight: \$20M Series B for AI-powered clinical-trial imaging endpoints | Jul. 30, 2026

Qureight raised a Series B led by Molten Ventures, with Hargreave Hale AIM VCT, XTX Ventures, Guinness Ventures, Meltwind and Ascension participating. Funds will expand its 3D deep-learning imaging portfolio for lung and heart disease trials.

HDIG take: Clinical-trials enablement: converts imaging, biomarkers and clinical data into scalable precision endpoints. [LINK](#)

9. Ractigen Therapeutics: Over RMB 200M new financing plus FDA IND clearance for ocular saRNA candidate | Jul. 30-31, 2026

CB Insights surfaced a late-July financing for Ractigen; ChinaVenture reported the company completed a new round exceeding RMB 200M. Separately, Ractigen announced U.S. FDA IND clearance for RAG-1C for proliferative vitreoretinopathy.

HDIG take: RNA therapeutics: capital and regulatory progress support a clinical-stage saRNA platform across oncology, neurological and genetic diseases. [LINK](#); [LINK](#)

10. Mindera Health: \$30.4M Series B tracked for precision dermatology decision support | Jul. 28, 2026

CB Insights tracked a \$30.4M Series B for Mindera Health, whose dermal biomarker patch and transcriptomic analysis platform helps guide psoriasis biologic selection for providers and payers.

HDIG take: Precision medicine: applies molecular diagnostics and software analytics to specialty-drug utilization. [LINK](#)

Upcoming Healthcare Events

Date	Event	Location	Why it matters
Aug. 10-12, 2026	2026 MATRC Telehealth Summit	Herndon, VA	Connected-care summit with healthcare leaders, policymakers and community organizations; includes a dedicated rural health track.
Aug. 19-20, 2026	Future BioTech Expo 2026	Houston, TX	Life-sciences and red-biotech conference at the Houston/Texas Medical Center ecosystem, with pharma, biotech CEOs, investors and policymakers.
Aug. 30-Sep. 2, 2026	PVA Healthcare Summit + Expo	Las Vegas, NV	Clinical and interdisciplinary healthcare summit focused on spinal cord injury/disease, MS and ALS care, with 50+ sessions and 100+ speakers.